secwatch / observer

8-K filed December 16, 2025, 6:59 PM ET ticker NKTR CIK 0000906709

other material confidence high sentiment positive materiality 0.70

Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.

NEKTAR THERAPEUTICS

Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.
Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.
Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.
Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-320009
form_type: 8-K
ticker: NKTR
cik: 0000906709
company_name: NEKTAR THERAPEUTICS
filed_at: 2025-12-16T23:59:59+00:00
discovered_at: 2026-05-14T18:02:42.555864+00:00
generated_at: 2026-05-16T13:08:58.707258+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-320009
json_url: https://secwatch.observer/filing/0001193125-25-320009.json
markdown_url: https://secwatch.observer/filing/0001193125-25-320009.md
text_url: https://secwatch.observer/filing/0001193125-25-320009.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/0001193125-25-320009-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/d24251d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-320009

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.